Stress-management intervention to prevent family violence

Stress and its management influence the nature of family interactions. Harmful family interactions, including violent interactions, are likely affected by mismanaged stress. This paper reviews scientific evidence on stress concepts, sources, and treatment strategies. Particular emphasis is given to the potential of stress-management preventive intervention for reducing the risk of family violence. Based on a study with teenage parents, the authors describe procedures and results from clinical stress-management preventive intervention. Study findings noted post-test and 3- month follow-up improvements in favor of preventive intervention subjects relative to test-only control subjects on measures of personal and social support, cognitive problem solving, self-reinforcement, parenting competence and care, and interpersonal performance. Consumer satisfaction from teenage parents who received intervention lent additional support to the value of stress-management preventive methods. The paper discusses the implications, limitations, and future directions of stress-management preventive intervention to lower risks of family violence.     

DNA as patentable subject matter and a narrow framework for addressing the perceived problems caused by gene patents

Concerns about the alleged harmful effects of gene patents--including hindered research and innovation and impeded patient access to high-quality genetic diagnostic tests--have resulted in overreactions from the public and throughout the legal profession. These overreactions are exemplified by Association for Molecular Pathology v. U.S. Patent and Trademark Office, a 2010 case in the Southern District of New York that held that isolated DNA is unpatentable subject matter under 35 U.S.C. § 101. The problem with these responses is that they fail to adequately consider the role that gene patents and patents on similar biomolecules play in facilitating investment in the costly and risky developmental processes required to transform the underlying inventions into marketable products. Accordingly, a more precisely refined solution is advisable. This Note proposes a narrowly tailored set of solutions to address the concerns about gene patents without destroying the incentives for companies to create and commercialize inventions derived from these and similar patents.